Drug intelligence / Profile preview

[68Ga]Ga-SCH001

Development stage
Unknown
Lead developer
First Affiliated Hospital of Soochow University
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
Administration
Intravenous
01

Overview

[68Ga]Ga-SCH001 is a novel gallium-68 labeled cyclic peptide radiopharmaceutical that targets CD38. It is being developed as a positron emission tomography (PET) imaging tracer for the non-invasive visualization of CD38 expression, assessment of whole-body tumor burden, and monitoring of early therapeutic response in patients with multiple myeloma and other plasma cell disorders (such as POEMS syndrome). The tracer consists of the cyclic peptide SCH001, which has high affinity and specificity for CD38, conjugated to a chelator (such as NOTA) and radiolabeled with gallium-68. In clinical studies, [68Ga]Ga-SCH001 has demonstrated rapid blood clearance, favorable radiation dosimetry, and high-contrast imaging of focal skeletal lesions in multiple myeloma.

Other names
[68Ga]Ga-NOTA-SCH00168Ga-SCH001Ga-SCH001Ga-SCH-001Ga-SCH 001
02

Targets

CD38 (Cluster of Differentiation 38)

Beyond the preview

Go deeper on [68Ga]Ga-SCH001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [68Ga]Ga-SCH001.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call